NextCure (NXTC) Stock Price, News & Analysis

Company Overview

NextCure, Inc. is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is centered on restoring or strengthening the immune system’s ability to recognize and attack tumor cells, with an emphasis on immune-suppressive mechanisms within the tumor microenvironment.

NextCure’s pipeline has included NC318, an investigational antibody designed to target Siglec-6, and NC410, an investigational fusion protein intended to interfere with the LAIR-2 immune-regulatory pathway. These programs have been evaluated in clinical studies for advanced solid tumors, both as standalone therapies and, where applicable, in combination with other cancer treatments.

Founded in 2015 and headquartered in the United States, NextCure has advanced its programs through early-stage clinical development and research collaborations. The company’s activities are primarily focused on oncology drug discovery and development, with its investigational products not yet broadly marketed as approved treatments.

Key Stats

• Today's Range: $5.32 to $6.30
• 50-Day Range: $4.14 to $8.42
• 52-Week Range: $1.55 to $15.74
• Volume: 125,886 shs
• Average Volume: 94,331 shs
• Market Capitalization: $19.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Hold

NextCure Stock Analysis - MarketRank™

NextCure scored higher than 71% of companies evaluated by MarketBeat, and ranked 200th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

NextCure has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NextCure has a consensus price target of $19.00, representing about 248.0% upside from its current price of $5.46.

Amount of Analyst Coverage

NextCure has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NextCure is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NextCure is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NextCure has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.45% of the float of NextCure has been sold short.

Short Interest Ratio / Days to Cover

NextCure has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NextCure has recently decreased by 68.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NextCure does not currently pay a dividend.

Dividend Growth

NextCure does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NXTC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

2 people have added NextCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,710,807.00 in company stock, which represents 8.6748% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, NextCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,710,807.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

11.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NXTC
• CIK: 1661059
• Web: www.nextcure.com
• Phone: (240) 399-4900
• Fax: N/A
• Employees: 40
• Year Founded: 2015

Price Target and Rating

• Average Price Target for NextCure: $19.00
• High Price Target: $20.00
• Low Price Target: $18.00
• Potential Upside/Downside: +248.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -154.62%
• Return on Assets: -100.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.47
• Quick Ratio: 3.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.97 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 3,610,000
• Free Float: 3,182,000
• Market Cap: $19.71 million
• Optionable: No Data
• Beta: 1.33